Core Insights - Cellectis announced the acceptance of two abstracts for poster presentations at the ASH 2025 annual meeting, focusing on its innovative gene-editing platform for cell and gene therapies [1] Group 1: Development Updates on eti-cel - The first poster presents a development update on eti-cel (UCART20x22), an allogeneic dual CAR-T therapy targeting CD20 and CD22, currently in Phase 1 of the NATHALI-01 clinical trial for relapsed/refractory non-Hodgkin lymphoma (r/r NHL) [2] - Preliminary results for eti-cel show an overall response rate (ORR) of 86% and a complete response (CR) rate of 57% among 7 patients, indicating a strong potential to improve outcomes for r/r NHL patients [3] - The addition of low-dose interleukin-2 (IL-2) is expected to enhance the anti-tumor activity of eti-cel, with full Phase 1 dataset presentation anticipated in 2026 [4][6] Group 2: Correlation with alemtuzumab in lasme-cel - The second poster discusses the correlation between alemtuzumab exposure and response in patients treated with lasme-cel (UCART22) during Phase 1 of the BALLI-01 trial for relapsed/refractory acute lymphoblastic leukemia (ALL) [5] - Data indicates a threshold level of alemtuzumab exposure that increases the likelihood of achieving a complete response without raising toxicity levels [6][7] Group 3: Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using a pioneering gene-editing platform, with a unique allogeneic approach for CAR T immunotherapies [8] - The company maintains in-house manufacturing capabilities, positioning itself as one of the few end-to-end gene editing companies that control the entire cell and gene therapy value chain [8]